CD274 and neoplasm: In addition, it was reported that a significant increase in the therapeutic effect of anti-PD-L1 antibodies was obtained by associating an agonist of Toll-like receptor 3 (TLR3), that activated DC and increased infiltration of immune effector cells within the tumor, [125] or standard chemotherapy [126].